Drugs For Malaria Market Strategies, Growth Opportunities, and Forecast by 2031

The Drugs For Malaria Market is expected to register a CAGR of 8.5% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX million by 2031.

The report is segmented by Drugs For Malaria Market By Drug Class (Quinine, Chloroquine, Proguanil, Mefloquine, Pyrimethamine, Others); Distribution (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Other Distribution Channels), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Drugs For Malaria Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

• Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
• Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
• Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Drugs For Malaria Market Segmentation

Drug Class

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Pyrimethamine
• Others

Distribution

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce
• Other Distribution Channels

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Drugs For Malaria Market Growth Drivers

• Rising Prevalence of Malaria: According to the World Health Organization (WHO), Malaria is an acute febrile illness caused by plasmodium parasites, which spread through the bites of infected female Anopheles mosquitoes. Malaria is caused by 5 parasite species in humans, and 2 of these species—Plasmodium falciparum and P. vivax—pose the greatest threat. P. falciparum is the deadliest malarial parasite, and it is the most widespread one on the African continent. P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa.
• Rising Cases of Malaria: According to the latest World malaria report (WMR) 2020, from the WHO, 241 million cases of malaria were reported in the world in 2020, compared to 227 million cases recorded in 2019. The number of deaths caused due to malaria stood at 0.62 million in 2020, with an annual rise of 69,000 deaths. While about two-thirds of these deaths (47,000) were due to disruptions in healthcare services during the COVID-19 pandemic, the remaining one-third of deaths (22,000) reflected a recent change in WHO’s the methodology for calculating malaria mortality (irrespective of COVID-19 disruptions)
• Rising cases in Nigeria and Congo: The WHO’s African region continues to account for a disproportionately high share of the global burden of malaria. In 2020, 95% of the global cases of malaria and 96% of deaths were reported in Africa; ~80% of the total deaths caused by malaria are reported in children below 5 years of age. Four African countries—Nigeria (31.9%), the Democratic Republic of the Congo (13.2%), the United Republic of Tanzania (4.1%), and Mozambique (3.8%)—accounted for nearly half of all malaria-related deaths reported worldwide

Drugs For Malaria Market Future Trends

• Government and Private Sector’s Initiatives: Malaria awareness campaigns help enhance knowledge regarding the disease and improve behaviors promoting health, along with promoting intersectoral collaboration and social support. The WHO coordinates the Global Malaria Programme (GMP) as part of its global efforts to control and eradicate malaria. The program is led by the "Global Technical Strategy for Malaria 2016-2030" adopted by the World Health Assembly in May 2015, which was further restructured in 2021. The WHO observes 25 April as World Malaria Day every year to highlight the collective energy and commitment of the malaria communities across the world in uniting around the common objective of freeing the world from malaria.
• National Framework for Malaria Elimination: In 2016, India introduced its first National Framework for Malaria Elimination, which will be valid from 2016 through 2030. In 2019, the Indian government raised funding by more than 25% for the National Vector Borne Disease Control Programme, launched in 2003. The country has also increased its contribution as a donor to the Global Fund to fight Malaria.
• Increased Awareness and Education: In the US, efforts for controlling malaria are made primarily through the President's Malaria Initiative (PMI), overseen by the US Global Malaria Coordinator. According to the Global Health Policy, the US planned the funding of ~US$ 1 billion in FY 2022 for malaria control and research activities. The goal of the US government under the PMI Strategy 2021-2026 is to manage malaria and reduce deaths caused by it, along with a long-term aim of eradicating the disease.

Drugs For Malaria Market Opportunities

• Emerging Markets: Several governments are taking initiatives to create awareness and conduct research for the development of new antimalarial drugs and vaccines. As per the WHO data, total funding for the control and elimination of malaria reached ~US$ 3 billion in 2019; the governments of endemic countries, collectively, contributed 31% (~US$ 900 million) of the total fund to create awareness and development of new vaccines. Private companies are also engaging in the fight against malaria and investing heavily in R&D activities. For instance, in 2018, Novartis invested more than US$ 100 million to enhance its research and development activities for next-generation treatments by 2023.
• Increased Market Competition: Myanmar has a national malaria control plan that is approved by the Global Fund, and it expects to eliminate the disease caused by P. falciparum by 2030. The universal healthcare coverage in the country includes access to malaria diagnosis by microscopy or rapid diagnostic tests (RDTs) and the availability of artemisinin-based combination therapies (ACTs).
• Extending Pipeline of New Drugs and Vaccines: Antimicrobial resistance threatens the public health response to many diseases, such as malaria, and the R&D of new medicines is the best strategy to overcome this challenge. With this, the antimalarial drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities in the malaria treatment market, creating lucrative opportunities for the market growth. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, is working with a large number of pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

Drugs For Malaria Market Regional Insights

The regional trends and factors influencing the Drugs For Malaria Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Drugs For Malaria Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Drugs For Malaria Market Report Scope

Drugs For Malaria Market Players Density: Understanding Its Impact on Business Dynamics

The Drugs For Malaria Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Drugs For Malaria Market are:

1. Alvizia Healthcare Pvt. Ltd.
2. Bayer AG
3. F. Hoffmann-La Roche Ltd
4. GlaxoSmithKline Plc
5. Ipca Laboratories Ltd.

Disclaimer: The companies listed above are not ranked in any particular order.

Key Selling Points

• Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Drugs For Malaria Market, providing a holistic landscape.
• Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
• Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
• Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Drugs For Malaria Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.